Results 161 to 170 of about 70,337 (231)

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data. [PDF]

Front Pharmacol, 2022
Zhao Q, Ma P, Fu P, Wang J, Wang K, Chen L, Yang Y.   +6 more
europepmc   +1 more source

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis. [PDF]

Technol Cancer Res Treat
Duan Q, Feng Y, Cao L, Hu L, Wang J, Sun F, Meng Q, Zhou M, Yu J, Gao H.   +9 more
europepmc   +1 more source

Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. [PDF]

JCO Precis Oncol, 2022
Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B.   +5 more
europepmc   +1 more source

Therapy-related myeloid neoplasms in Korean patients with ovarian or primary peritoneal cancer treated with poly(ADP-ribose) polymerase inhibitors. [PDF]

Transl Cancer Res
Jang YJ, Kim H, Ryu SY, Kim MH, Kim BJ, Jung HJ, Kang J, Yang SH, Na II, Lee HR, Kang HJ.   +10 more
europepmc   +1 more source

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <i>BRCA1</i>/<i>2</i>, Germline <i>PALB2</i>, or Homologous Recombination Deficiency Signature. [PDF]

JCO Precis Oncol, 2023
Batalini F, Madison RW, Sokol ES, Jin DX, Chen KT, Decker B, Pavlick DC, Frampton GM, Wulf GM, Garber JE, Oxnard G, Schrock AB, Tung NM.   +12 more
europepmc   +1 more source

Are Poly (ADP-Ribose) Polymerase Inhibitors Safe in Paraneoplastic Dermatomyositis due to High-Grade Serous Carcinoma of the Ovary? A Case Report and a Review of the Literature. [PDF]

Case Rep Oncol
Koheeallee K, Sarivalasis A.
europepmc   +1 more source

Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis. [PDF]

Front Oncol
Huang R, Ji F, Huang L, Qin Y, Liang Z, Huang M, Li C, Ban J.   +7 more
europepmc   +1 more source

Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors. [PDF]

Zhejiang Da Xue Xue Bao Yi Xue Ban, 2022
Society of Obstetrics and Gynecology of Zhejiang Medical Association, Society of Urology of Zhejiang Medical Association, Committee of Breast Cancer of Zhejiang Anticancer Association, Committee of Clinical Pharmacy on Oncology of Zhejiang Anticancer Association (preparation), Committee of Urology of Zhejiang Society for Mathematical Medicine.   +4 more
europepmc   +1 more source

Colon-Targeted Poly(ADP-ribose) Polymerase Inhibitors Synergize Therapeutic Effects of Mesalazine Against Rat Colitis Induced by 2,4-Dinitrobenzenesulfonic Acid. [PDF]

Pharmaceutics
Kang C, Kim J, Jeong Y, Yoo JW, Jung Y.
europepmc   +1 more source

Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. [PDF]

Adv Ther, 2022
Arend RC, O'Malley DM, Banerjee S, McLaurin K, Davidson R, Long GH.   +5 more
europepmc   +1 more source